Prophase Lab News Today

ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) – Diamond Equity issued their Q1 2025 EPS estimates for shares of ProPhase Labs in a note issued to investors on Monday, April 22nd. Diamond Equity analyst H. Diamond forecasts that the company will post earnings per share of $0.10 for the quarter. The consensus estimate for ProPhase […]

ProPhase Labs, Inc. (NASDAQ: PRPH) saw its shares lose some strength Wednesday, as the next-generation biotech, genomics, and diagnostics company, reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. ...

ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) – HC Wainwright dropped their Q3 2023 EPS estimates for ProPhase Labs in a report released on Monday, August 14th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.19) for the quarter, down from their prior forecast of ($0.17). HC […]

Garden City, NY, Aug. 10, 2023 -- ProPhase Labs, Inc. Conference Call and Webcast Details Management will host a conference call at 11:00 AM ET, Thursday, August 10, 2023, to provide an update... -Today at 10:40 am- MarketScreener

RAPT Therapeutics (NASDAQ:RAPT – Free Report) and ProPhase Labs (NASDAQ:PRPH – Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk. Analyst Ratings This is a breakdown of recent ratings […]

DSS, Inc.

Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics...

Disc Medicine Opco (NASDAQ:IRON – Get Rating) and ProPhase Labs (NASDAQ:PRPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership. Institutional and Insider Ownership 75.4% of Disc Medicine […]

Disc Medicine Opco (NASDAQ:IRON – Get Rating) and ProPhase Labs (NASDAQ:PRPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability. Volatility and Risk Disc Medicine Opco has a […]

In line with their collaboration, G42 Healthcare and ProPhase will also explore the creation of a genomic sequencing facility in the US